<DOC>
	<DOC>NCT01226953</DOC>
	<brief_summary>This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age</brief_summary>
	<brief_title>Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants 365569 days of age. Subjects who already received a booster dose of Hib vaccine. History of serious reaction(s) following vaccination. Any vaccination within 7 days of study vaccination. Known or suspected immune impairment.</criteria>
	<gender>All</gender>
	<minimum_age>365 Days</minimum_age>
	<maximum_age>569 Days</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Haemophilus influenzae type b (Hib)</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Anti-PRP antibody</keyword>
</DOC>